On July 9, 2024, Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced that it has acquired Fluent BioSciences (Fluent), developer of an emerging and highly differentiated single-cell technology. Wilson Sonsini Goodrich & Rosati advised Fluent on the transaction.
The integration of Fluent's accessible and flexible single-cell method is expected to improve Illumina's ability to provide comprehensive multiomics solutions to its customers. Fluent's team will join Illumina as they aim to develop end-to-end solutions for single-cell analysis. Illumina intends to remain an open NGS platform and continue supporting its existing single-cell partnerships.
The Wilson Sonsini team that advised Fluent includes:
Corporate
Mark Solakian
Priyanka Nawathe
Reilly Clark
Steven Song
Alex DeLaney
M&A
Ethan Lutske
Dennise Martinez
Austin Wolfe
Delaware Law
Ryan Greecher
Jason Schoenberg
Technology Transactions
Mark Bellomy
Sarah (Siedlak) Walker
Lauren Wardle
Isabel Annino
Barclay Oudersluys
Brittany Von Rueden
Employee Benefits and Compensation
Lori Howey
Matthew Norgard
Employment Law
Matthew Gorman
Ryan Gribbin-Burket
Privacy and Cybersecurity
Matt Staples
Daniel Chen
Chany Kim
Dantam Le
National Security
Josephine Aiello LeBeau
Seth Cowell
Anne Seymour
Kara Millard
Real Estate
James McCann
Moncarol Wang
For more information, please see Illumina's news release. Additional coverage can be found on MarketWatch, MedTech Dive, and Fierce Biotech.